Your diagnostic partner in Hemophilia
Versiti’s Factor VIII Chromogenic Assay (all-bovine reagent) is recommended for measuring endogenous or infused factor VIII activity and inhibitors, including the monitoring of patients with hemophilia A receiving emicizumab-kxwh.
Available Summer 2019
Advantages of Versiti's Factor VIII Chromogenic Assay:
Versiti’s Factor VIII Chromogenic Activity (all-bovine reagent) is can be used in the diagnosis of nonsevere hemophilia A, and useful in the accurate determination of factor VIII (FVIII) activity in the presence of a lupus anticoagulant or when certain modified recombinant FVIII replacement products are present, such as domain deleted Factor VIII formulations.
More about Hemophilia A:
Hemophilia A is an X-linked inherited bleeding disorder caused by mutation of the factor VIII (FVIII) gene that encodes for coagulation factor VIII. The degree of plasma factor deficiency correlates with both the clinical severity of disease and genetic findings.